Alzheimer's Disease Therapeutics and Diagnostics: Global Markets

  • ID: 3672798
  • Report
  • Region: Global
  • 144 Pages
  • BCC Research
20 % OFF
until Jun 30th 2018
1 of 5
The Growing Alzheimer's Disease Population is Driving the Market and Raising Treatment Urgency

FEATURED COMPANIES

  • AB Science
  • Allergan PLC
  • Axon Neuroscience
  • Daiichi Sankyo Co
  • F. Hoffmann La Roche AG
  • Merck & Co
  • MORE
The global market for AD therapeutics and diagnostics by region should reach over $6.2 billion by 2020 from $4.4 billion in 2015, at a compound annual growth rate (CAGR) of 7.1% from 2015 to 2020.

This report provides:

- An overview of the global market for Alzheimer's disease therapeutic and diagnostic technologies
- Analyses of global market trends, with data from 2014, estimates for 2015, and projections of compound annual growth rates (CAGRs) through 2020
- Review of programs in development and quantification of market opportunities
- Discussion of the market segments' economic environment, technological descriptions and issues, and applications
- Projections of usage in the major primary and secondary disease application areas
- Profiles of major players in the industry

Scope of the Study:

The scope of this study encompasses the global and regional markets for Alzheimer’s therapeutics and diagnostics. These markets are segmented by branded and generic drugs, mechanism of action, such as acetylcholine inhibitors (AChEIs) and N-methyl-D-aspartate (NMDA) receptor antagonists, a combination drug of donepezil and memantine, tau aggregation inhibitors (TAI) and amyloid-beta (Aß) vaccines. Drugs are also segmented by the stage of Alzheimer’s disease they treat: mild to moderate, severe and prodromal.

Each market and its applications are analyzed, together with the regulatory environment, assistive technologies, market projections and market share. Issues discussed include the major drug profiles, clinical groundwork, technological features and trends. The regional markets for AD therapeutics and diagnostics include selected markets in the U.S., Canada, the U.K., France, Germany, Italy, Spain, Japan, China and India. These markets are grouped as North America, Europe and Asia-Pacific. The rest of the world markets are not addressed because of their economic insignificance with respect to this report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AB Science
  • Allergan PLC
  • Axon Neuroscience
  • Daiichi Sankyo Co
  • F. Hoffmann La Roche AG
  • Merck & Co
  • MORE
Chapter 1: Introduction
- Study Objectives
- Reasons For Doing The Study
- Intended Audience
- Scope Of The Study
- Information Sources
- Methodology
- Analyst's Credentials

Chapter 2: Summary
- Table Summary : Global Market For Alzheimer's Therapeutics And Diagnostics By Region, Through 2020
- Figure Summary : Global Market For Alzheimer's Therapeutics And Diagnostics By Region, 2014-2020

Chapter 3: Overview
- Alzheimer's Disease: Definition And Market Structure
- Alzheimer's Disease Pathophysiology
- Alzheimer's Disease Etiology
- Alzheimer's Disease Epidemiology
- Diagnosis And Treatment Of Alzheimer's

Chapter 4: Regulatory Landscape
- U.S. Food And Drug Administration
- European Medicines Agency

Chapter 5: Global Markets
- Introduction
- Market Dynamics
- Global Market For Ad Therapeutics And Diagnostics

Chapter 6: North American Market For Alzheimer's Therapeutics And Diagnostics

- North American Market

Chapter 7: European Markets For Alzheimer's Therapeutics And Diagnostics

- European Markets

Chapter 8: Asia-Pacific Market For Alzheimer's Therapeutics And Diagnostics

- Asia-Pacific Market

Chapter 9: Pipeline Analysis

- AD Pipeline Landscape
- AD Pipeline: Clinical Stage
- AD Pipeline: Treatment Focus
- AD Pipeline By Disease Stage
- AD Pipeline: Mechanism Of Action
- Major AB-Based Therapies In Clinical Trials
- Major TAU-Based Therapies In Clinical Trials

Chapter 10: Companion Diagnostics

- Introduction
- Companion Imaging Diagnostics For AD

Chapter 11: Company Profiles

- AB Science
- Abbvie Inc.
- AC Immune SA
- Allergan PLC
- Affiris AG
- Amarantus Bioscience Holdings
- Anavex Life Sciences
- Astrazeneca
- Avid Radiopharmaceuticals
- Axon Neuroscience
- Axovant Sciences
- Biogen
- Boehringer Ingelheim
- Daiichi Sankyo Co
- Diagenic
- Eisai
- Eli Lilly
- F. Hoffmann La Roche AG
- GE Healthcare
- H. Lundbeck A/S
- Janssen Pharmaceuticals
- Merck & Co
- Navidea Biopharmaceuticals
- Neurotrax Corp.
- Novartis Pharma Services AG
- Ono Pharmaceutical Co.
- Otsuka Pharmaceuticals
- Pfizer Inc
- Piramal Imaging Gmbh
- Taurx Therapeutics

List Of Tables

Summary Table : Global Market For Alzheimer's Therapeutics And Diagnostics By Region, Through 2020
Table 1 : Prevalence Rates Of Alzheimer's By Region, 2014
Table 2 : Global Alzheimer's Population By Age Group And Region, 2014
Table 3 : Pharmacological Treatment Of Bpsd Of Alzheimer's
Table 4 : Computerized Screening Tests Used In Detecting Cognitive Impairment
Table 5 : Brain Imaging Technologies And Application In The Alzheimer's Context
Table 6 : Diagnostic Imaging Tracers Approved By The Fda
Table 7 : Global Market Shares Of Leading Companies In Alzheimer's Therapeutics, 2020
Table 8 : Global Market For Alzheimer's Therapeutics And Diagnostics By Region, Through 2020
Table 9 : Global Market For Alzheimer's Therapeutics And Diagnostics By Application, Through 2020
Table 10 : Global Market For Alzheimer's Therapeutics By Region, Through 2020
Table 11 : Global Market For Generic/Branded Alzheimer's Therapeutics, Through 2020
Table 12 : Global Market For Alzheimer's Therapeutics By Mechanism Of Action, Through 2020
Table 13 : Global Market For Branded/Generic Acetylcholinesterase Inhibitors, Through 2020
Table 14 : Global Market For Acetylcholinesterase Inhibitors By Region, Through 2020
Table 15 : Global Market For Branded/Generic Nmda Drugs, Through 2020
Table 16 : Global Market For Nmda Drugs By Region, Through 2020
Table 17 : Global Market For Other Alzheimer's Therapeutics By Region, Through 2020
Table 18 : Global Market For Alzheimer's Therapeutics By Disease Stage, Through 2020
Table 19 : Global Market For Alzheimer's Diagnostics By Region, Through 2020
Table 20 : Global Market For Alzheimer's Diagnostics By Molecular Target, Through 2020
Table 21 : North American Market For Alzheimer's Therapeutics And Diagnostics By Application Segment, Through 2020
Table 22 : North American Market For Alzheimer's Therapeutics By Country, Through 2020
Table 23 : North American Market For Branded/Generic Alzheimer's Therapeutics, Through 2020
Table 24 : North American Market For Alzheimer's Therapeutics By Mechanism Of Action, Through 2020
Table 25 : North American Market For Branded/Generic Acetylcholinesterase Inhibitors, Through 2020
Table 26 : North American Market For Acetylcholinesterase Inhibitors By Country, Through 2020
Table 27 : North American Market For Branded/Generic Nmda Drugs, Through 2020
Table 28 : North American Market For Nmda Drugs By Country, Through 2020
Table 29 : North American Market For Other Alzheimer's Therapeutics By Country, Through 2020
Table 30 : North American Market For Alzheimer's Therapeutics By Disease Stage, Through 2020
Table 31 : North American Market For Alzheimer's Diagnostics By Molecular Target, Through 2020
Table 32 : European Market For Alzheimer's Therapeutics And Diagnostics By Application Segment, Through 2020
Table 33 : European Market For Alzheimer's Therapeutics By Country, Through 2020
Table 34 : European Market For Branded/Generic Alzheimer's Therapeutics, Through 2020
Table 35 : European Market For Alzheimer's Therapeutics By Mechanism Of Action, Through 2020
Table 36 : European Market For Branded/Generic Acetylcholinesterase Inhibitors, Through 2020
Table 37 : European Market For Acetylcholinesterase Inhibitors By Country, Through 2020
Table 38 : European Market For Branded/Generic Nmda Drugs, Through 2020
Table 39 : European Market For Nmda Drugs By Country, Through 2020
Table 40 : European Market For Other Alzheimer's Therapeutics By Country, Through 2020
Table 41 : European Market For Alzheimer's Therapeutics By Disease Stage, Through 2020
Table 42 : European Market For Alzheimer's Diagnostics By Molecular Target, Through 2020
Table 43 : Asia-Pacific Market For Alzheimer's Therapeutics And Diagnostics By Application Segment, Through 2020
Table 44 : Asia-Pacific Market For Alzheimer's Therapeutics By Country, Through 2020
Table 45 : Asia-Pacific Market For Branded/Generic Alzheimer's Therapeutics, Through 2020
Table 46 : Asia-Pacific Market For Alzheimer's Therapeutics By Mechanism Of Action, Through 2020
Table 47 : Asia-Pacific Market For Branded/Generic Acetylcholin-Esterase Inhibitors, Through 2020
Table 48 : Asia-Pacific Market For Acetylcholinesterase Inhibitors By Country, Through 2020
Table 49 : Asia-Pacific Market For Branded/Generic Nmda Drugs, Through 2020
Table 50 : Asia-Pacific Market For Nmda Drugs By Country, Through 2020
Table 51 : Asia-Pacific Market For Alzheimer's Therapeutics By Disease Stage, Through 2020
Table 52 : Asia-Pacific Market For Alzheimer's Diagnostics By Molecular Target, Through 2020
Table 53 : Global Alzheimer's Drugs In The Pipeline By Mechanism Of Action
Table 54 : Cidx-Drug Pairs In Clinical Trials

List Of Figures

Summary Figure : Global Market For Alzheimer's Therapeutics And Diagnostics By Region, 2014-2020
Figure 1 : Change In Alzheimer's Population And Cost Of Care In The U.S., 2015-2030
Figure 2 : Global Prevalence Rates Of Alzheimer's By Age Group And Region
Figure 3 : Global Alzheimer's Population By Age Group And Region, 2014
Figure 4 : Global Market Shares Of Leading Companies In Alzheimer's Therapeutics, 2020
Figure 5 : Global Market Shares Of Alzheimer's Therapeutics And Diagnostics By Region, 2015
Figure 6 : Global Market For Alzheimer's Therapeutics And Diagnostics By Region, 2014-2020
Figure 7 : Global Market For Alzheimer's Therapeutics And Diagnostics By Application, 2014-2020
Figure 8 : Global Market For Alzheimer's Therapeutics By Region, 2014-2020
Figure 9 : Global Market For Branded/Generic Alzheimer's Therapeutics, 2014-2020
Figure 10 : Global Market For Alzheimer's Therapeutics By Mechanism Of Action, 2014-2020
Figure 11 : Global Market For Branded/Generic Acetylcholinesterase Inhibitors, 2014-2020
Figure 12 : Global Market For Acetylcholinesterase Inhibitors By Region, 2014-2020
Figure 13 : Global Market For Branded/Generic Nmda Drugs, 2014-2020
Figure 14 : Global Market For Nmda Drugs By Region, 2014-2020
Figure 15 : Global Market For Other Alzheimer's Therapeutics By Region, 2014-2020
Figure 16 : Global Market For Alzheimer's Therapeutics By Disease Stage, 2014-2020
Figure 17 : Global Market For Alzheimer's Diagnostics By Region, 2014-2020
Figure 18 : Global Market For Alzheimer's Diagnostics By Molecular Target, 2014-2020
Figure 19 : North American Market For Alzheimer's Therapeutics And Diagnostics By Application Segment, 2014-2020
Figure 20 : North American Market For Alzheimer's Therapeutics By Country, 2014-2020
Figure 21 : North American Market For Branded/Generic Alzheimer's Therapeutics, 2014-2020
Figure 22 : North American Market For Alzheimer's Therapeutics By Mechanism Of Action, 2014-2020
Figure 23 : North American Market For Branded/Generic Acetylcholinesterase Inhibitors, 2014-2020
Figure 24 : North American Market For Acetylcholinesterase Inhibitors Market By Country, 2014-2020
Figure 25 : North American Market For Branded/Generic Nmda Drugs, 2014-2020
Figure 26 : North American Market For Nmda Drugs By Country, 2014-2020
Figure 27 : North American Market For Other Alzheimer's Therapeutics By Country, 2014-2020
Figure 28 : North American Market For Alzheimer's Therapeutics By Disease Stage 2014-2020
Figure 29 : North American Market For Alzheimer's Diagnostics By Molecular Target, 2014-2020
Figure 30 : European Market For Alzheimer's Therapeutics And Diagnostics By Application Segment, 2014-2020
Figure 31 : European Market For Alzheimer's Therapeutics By Country, 2014-2020
Figure 32 : European Market For Branded/Generic Alzheimer's Therapeutics, 2014-2020
Figure 33 : European Market For Alzheimer's Therapeutics By Mechanism Of Action, 2014-2020
Figure 34 : European Market For Branded/Generic Acetylcholinesterase Inhibitors, 2014-2020
Figure 35 : European Market For Acetylcholinesterase Inhibitors By Country, 2014-2020
Figure 36 : European Market For Branded/Generic Nmda Drugs, 2014-2020
Figure 37 : European Market For Nmda Drugs By Country, 2014-2020
Figure 38 : European Market For Other Alzheimer's Therapeutics By Country, Through 2020
Figure 39 : European Market For Alzheimer's Therapeutics By Disease Stage, 2014-2020
Figure 40 : European Market For Alzheimer's Diagnostics By Molecular Target, 2014-2020
Figure 41 : Asia-Pacific Market For Alzheimer's Therapeutics And Diagnostics By Application Segment, 2014-2020
Figure 42 : Asia-Pacific Market For Alzheimer's Therapeutics By Country, Through 2020
Figure 43 : Asia-Pacific Market For Branded/Generic Alzheimer's Therapeutics, 2014-2020
Figure 44 : Asia-Pacific Market For Alzheimer's Therapeutics By Mechanism Of Action, 2014-2020
Figure 45 : Asia-Pacific Market For Branded/Generic Acetylcholin-Esterase Inhibitors, 2014-2020
Figure 46 : Asia-Pacific Market For Acetylcholinesterase Inhibitors By Country, 2014-2020
Figure 47 : Asia-Pacific Market For Branded/Generic Nmda Drugs, 2014-2020
Figure 48 : Asia-Pacific Market For Nmda Drugs By Country, 2014-2020
Figure 49 : Asia-Pacific Market For Alzheimer's Therapeutics By Disease Stage, 2014-2020
Figure 50 : Asia-Pacific Market For Alzheimer's Diagnostics By Molecular Target, 2014-2020
Figure 51 : Alzheimer's Drugs In The Pipeline By Development Stage
Figure 52 : Alzheimer's Drugs In The Pipeline By Treatment Focus
Figure 53 : Late Phase Ii/Iii Alzheimer's Drugs By Disease Stage
Figure 54 : Global Clinical Trials On Alzheimer's Drug By Mechanism Of Action
Figure 55 : Fda-Approved Cdx Technologies By Indicated Therapeutic Class
Figure 56 : Fda-Approved Cdx-Drug Pairs By Molecular Target
Figure 57 : Ongoing Ab And Tau Pet Imaging Clinical Trials
Figure 58 : Ab And Tau Pet Imaging Trials By Clinical Trial Phase
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
- AB Science
- Abbvie Inc.
- AC Immune SA
- Allergan PLC
- Affiris AG
- Amarantus Bioscience Holdings
- Anavex Life Sciences
- Astrazeneca
- Avid Radiopharmaceuticals
- Axon Neuroscience
- Axovant Sciences
- Biogen
- Boehringer Ingelheim
- Daiichi Sankyo Co
- Diagenic
- Eisai
- Eli Lilly
- F. Hoffmann La Roche AG
- GE Healthcare
- H. Lundbeck A/S
- Janssen Pharmaceuticals
- Merck & Co
- Navidea Biopharmaceuticals
- Neurotrax Corp.
- Novartis Pharma Services AG
- Ono Pharmaceutical Co.
- Otsuka Pharmaceuticals
- Pfizer Inc
- Piramal Imaging Gmbh
- Taurx Therapeutics
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll